Anticholinergic 3-[2-(azabicyclo)ethyl)-1,2,3,4-tetra- hydro-5H-[1]benzopyrano[3,4-c]pyridin-5-ones, useful for treating broncho-spastic diseases in mammals, are disclosed. Also disclosed are methods for preparing such novel compounds, and pharmaceutical compositions containing them. The novel compounds have the formula I:
wherein R 1 is a hydrogen atom, an alkyl radical having from 1 to 6 carbon atoms, an alkoxy radical having from 1 to 6 carbon atoms, or a hydroxy, nitro, halo, amino or acylamino radical; R 2 is a hydrogen atom, a hydroxy radical, an alkyl radical having from 1 to 6 carbon atoms, an alkoxy radical having from 1 to 6 carbon atoms or a phenyl radical; R 3 is a hydrogen atom or an alkoxy radical having from 1 to 6 carbon atoms; or R 1 and R 2 taken together are -OCH 2 0-; or R 2 and R 3 taken together are -CH=CH-CH=CH-; and
or a pharmaceutically acceptable salt thereof, provided that R 1 is not hydroxy when R 2 is -OC 2 H 5 and X is